Status:
UNKNOWN
A Study Using MRI To Assess Bladder Motion During Radiotherapy
Lead Sponsor:
The Christie NHS Foundation Trust
Conditions:
Bladder Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The standard non-surgical treatment for muscle invasive bladder cancer is concurrent chemo-radiotherapy. This treatment is associated with long term side effects in around a third of patients with up ...
Detailed Description
Patients will undergo standard treatment during the study with four weeks of external beam radiotherapy (20 fractions). They will be treated with weekly Gemcitabine (100mg/m2) or daily Nicotinamide (6...
Eligibility Criteria
Inclusion
- Histologically confirmed diagnosis of bladder cancer
- Treatment with primary curative intent
- Undergoing external beam radiotherapy (+/-chemotherapy)
- Age over 18 years
Exclusion
- Any contraindications to MRI identified after MRI safety screening including completion of an MRI Safety Screening Form
- Any contraindications to both Hyoscine Butylbromide (Buscopan)
- Previous cystectomy
- Unable to tolerate MRI scans
- Metastatic disease
- Pregnancy
Key Trial Info
Start Date :
March 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2019
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03409029
Start Date
March 1 2018
End Date
September 1 2019
Last Update
January 30 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.